Johnson & Johnson-backed Rapport Therapeutics secures USD 154 million in US IPO
Advertisement
London: Rapport Therapeutics,, backed by the venture capital arm of Johnson & Johnson has said that the Company has secured $154 million in its initial public offering (IPO) in the United States at a valuation of approximately $601.4 million.
The company intends to sell 8 million shares at $17 each, priced at the midpoint of its anticipated price range of $16-$18 apiece.
Rapport develops small molecule medicines for patients suffering from central nervous system disorders.
The Boston, Massachusetts-based company was formed in February 2022 with founding support from Third Rock Ventures and Johnson & Johnson Innovation-JJDC.
Initially named Precision Neuroscience NewCo, Rapport has said that it plans to use a portion of the IPO proceeds to advance the clinical development of its lead product candidate, RAP-219, for the treatment of focal epilepsy.
The IPO shows that the U.S. IPO market has made a strong comeback after two dismal years.
Companies have raised more than $15 billion this year via IPOs on U.S. exchanges, according to Dealogic, up sharply from about $9.1 billion at this point last year, the data shows.
Goldman Sachs, Jefferies, TD Cowen and Stifel are the underwriters for the offering.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.